Back to search results

D-mannose for Preventing Recurrent Urinary Tract Infections

This study is looking at whether a dietary supplement called D-mannose can help prevent recurrent urinary tract infections (UTIs) in post-menopausal women. You might be able to join if you are a woman aged 55 to 85, have gone through menopause, and have a history of frequent UTIs (at least 3 in 12 months or 2 in 6 months). You must also be free of a UTI when you join the study. Participants will either take D-mannose or a placebo (an inactive substance) daily for 12 months. The main goal is to see if D-mannose reduces the number of UTIs over an average of 5 years. The study is currently recruiting 90 participants.

Study design
This is a randomized, double-blind, placebo-controlled study, meaning participants are randomly assigned to receive either D-mannose or a placebo, and neither you nor your doctors will know which you are receiving. It plans to enroll 90 women.
What's involved
You would take D-mannose or a placebo daily for 12 months. The study will track your progress through study completion, an average of 5 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through study completion, an average of 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06940622

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

Recruiting
NAAges 55–85InterventionalPrevention
University of Texas Southwestern Medical Center
~90 participants
Updated 2025-09-22 on ClinicalTrials.gov
What's tested:D-MannosePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Failure rate
Measured over Through study completion, an average of 5 years

Conditions

Recurrent UTIs
Recurrent Urinary Tract Infections
Recurrent Urinary Tract Infections in Women
Recurrent Urinary Tract Infection
Cystitis Recurrent
Cystitis Chronic
UTI
UTI - Urinary Tract Infection
UTI - Lower Urinary Tract Infection

Explore related trials

Recurrent urinary tract infection

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Philippe Zimmern, MD · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center

Who to contact

Jessica de Araujo Paula
[email protected]
2146458787
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Female, post-menopausal, age ≥ 55 years old
Diagnosis of recurrent UTI, defined as ≥ 3 symptomatic culture-proven UTI episodes in 12 months or ≥ 2 in 6 months.
Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire79 and negative urine culture (\<103 colony forming units per ml of urine).
Able to attend all follow-up appointments for the study.
A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than stage 2), measurement of post-void residual (less than 50 ml), and imaging (renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum.

Exclusion

Current use of D-mannose. Patients willing to stop taking D-mannose will be offered to join the trial after a 4-week wash-out period.
Complicated UTIs, including need for catheter drainage or intermittent catheterization, neurogenic bladder, bladder augmentation, or urinary diversion.
Ongoing supplement use (Box 1). Patients willing to stop taking the listed supplements will be offered to join the trial after a 4-week wash-out period.
Evidence of upper tract infection (pyelonephritis), including temperature higher than 38°C, flank/lumbar pain or tenderness
Diagnosis of interstitial cystitis or overactive bladder syndrome
Prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months
Use of Uromune or other vaccine approaches to reduce rUTI
Participation in a research study involving an investigational product in the past 12 weeks
Receipt of phage treatment
History of chronic diarrhea requiring regular therapy
Inability to swallow or known history of gastrointestinal malabsorption
History of recurrent vaginal yeast infections
Systemic disease precluding enrollment in this study (uncontrolled diabetes with HgA1C above 7, ongoing chemotherapy or immunotherapy, renal insufficiency \[creatinine \> 1.5 g/dl\]), mental or cognitive impairment, weight loss diet requiring excessively large amounts of fluid intake, or other health-related specific diet).
Nursing home resident
BMI \>40
Multi-Vitamins and Multi-Mineral capsules
Specific Vitamins or Minerals (e.g., Calcium, Citrical, Calcium Gummies, Vitamin A, D, Niacin, Pyridoxine, Selenium, Vitamin E, B6, Iron, Omega 3, D3, Magnesium, B-Complex, Women's Ultra MultiVitamin, GNC B-Complex, B-12, PreserVision Areds2, Vitamins D, B Pollen)
Probiotics
Cranberry Mannose or Cranberry Extract Weight loss products to avoid
Medifast
Vitafusion
OptiVin Products
Appetite Suppressants
Keto-Fuel

What this trial measures

  • Failure rateThrough study completion, an average of 5 years

    To determine whether prophylaxis with D-mannose reduces the incidence of UTI episodes compared to placebo. "Failure rate," defined as having 2 UTIs in 6 months or 3 in one year.